Immunocore (NASDAQ:IMCR) Downgraded to “Hold” Rating by Zacks Research

Zacks Research lowered shares of Immunocore (NASDAQ:IMCR) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday,Zacks.com reports.

Several other brokerages have also recently issued reports on IMCR. Needham & Company LLC lifted their price objective on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group set a $55.00 price target on shares of Immunocore and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Mizuho set a $38.00 price objective on Immunocore in a research report on Thursday, February 19th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company started coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.30.

Immunocore Stock Down 0.4%

IMCR opened at $32.04 on Wednesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The company has a market capitalization of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. The stock’s fifty day moving average is $33.55 and its 200-day moving average is $34.32. Immunocore has a one year low of $23.15 and a one year high of $40.71.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, February 25th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.32). Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.16%. The firm had revenue of $104.48 million for the quarter, compared to the consensus estimate of $145.48 million. During the same period in the prior year, the business earned ($0.47) EPS. The company’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, equities analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Transactions at Immunocore

In other Immunocore news, insider Leger Tina Amber St sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider directly owned 1,119 shares in the company, valued at approximately $36,199.65. This trade represents a 47.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares in the company, valued at approximately $399,296.05. This trade represents a 48.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 19,137 shares of company stock valued at $619,082 over the last quarter. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Leonteq Securities AG purchased a new stake in Immunocore in the 4th quarter worth approximately $30,000. GAMMA Investing LLC grew its holdings in shares of Immunocore by 51.6% during the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after acquiring an additional 311 shares in the last quarter. Harbour Investments Inc. increased its stake in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Immunocore during the second quarter worth $42,000. Finally, Arax Advisory Partners raised its holdings in shares of Immunocore by 302.9% during the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after acquiring an additional 1,042 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.